The deal struck between the pharmaceutical lobby, the White House and Senate Democrats has drastically improved Big Pharma’s expected profits, a private industry report finds.
IMS Health, a company that supplies the pharmaceutical companies with sales data, predicts that new health reform legislation — combined with a projected upswing in the economy — will result in a net gain of more than $137 billion in total market sales over the next four years. The new assessment was contained in document obtained by the Huffington Post.
Back in March, that same firm projected a compound annual growth rate of -0.1 percent in the period of 2008 through 2013. In October, with the general outlines of health care reform clearly in place, it revised that number to a positive 3.5 percent for over the same period.